Genomma Lab stock: October 21 results are due for Genomma Lab stock
Published on 10/19/2026 at 16:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSScheduled results and valuation
- Genomma Lab is due to report third-quarter results on October 21, 2026.
- Consensus sees MXN 17.80 billion in 2026 revenue versus MXN 17.54 billion previously.
- Genomma Lab stock costs EUR 0.70 at Lang & Schwarz on October 19, 2026, with the BMV session up 1.34 percent versus its October 16 close.
- Genomma Lab has a market capitalization of MXN 14.1 billion and a P/E ratio of 8.60.
Genomma Lab is due to report third-quarter 2026 results on October 21, 2026, after the Mexican Stock Exchange closes, with a conference call scheduled for October 22. ScanX News reported the timetable on October 2, 2026. Genomma Lab stock was EUR 0.70 at Lang & Schwarz on October 19, 2026 at 4:02 p.m. CEST.
Revenue expectations point higher
Consensus estimates cited by finanzen.ch on October 6, 2026 put fiscal-year 2026 revenue at MXN 17.80 billion, compared with MXN 17.54 billion for the prior year. Seven analysts contributed to the revenue estimate, while one analyst projected earnings per share of MXN 0.46 for the upcoming quarter versus MXN 0.44 a year earlier.
Price sits below the yearly high
On the BMV, Genomma Lab traded at MXN 14.38 on October 19, 2026 at 7:46 a.m. CST, up 1.34 percent from the prior close of MXN 14.19. The finance data also placed the 52-week range at MXN 12.22 to MXN 19.48. The latest home-market price was 26.18 percent below the yearly high and 17.68 percent above the yearly low. Trading volume was 29,409 shares against an average of 3,512,320 shares as of October 19, 2026.
Valuation and scheduled dates
Genomma Lab's market capitalization was MXN 14.1 billion on October 19, 2026, and its P/E ratio was 8.60. Its trailing dividend yield was 0.06 percent. The October 21 results and the October 22 conference call give investors two fixed dates for reviewing revenue, earnings and management commentary.
Comparison with peers
Genomma Lab: plus 1.34 percent, P/E 8.60, market capitalization MXN 14.1 billion.
Kimberly-Clark de Mexico (BMV, MXN): minus 0.13 percent, P/E 14.97, market capitalization MXN 117.9 billion.
Coca-Cola FEMSA (BMV, MXN): plus 1.38 percent, P/E 19.31, market capitalization MXN 11.7 billion.
Price and investor dates
The euro quotation gives German investors a direct market indication, while the BMV figures provide the operating-market context. Genomma Lab's next reported results and conference call are scheduled for October 21 and October 22, 2026.
Genomma Lab stock was trading at EUR 0.70 at Lang & Schwarz on October 19, 2026 at 4:02 p.m. CEST; the BMV session was up 1.34 percent versus its October 16 close.
The further course of trading is shown by the continuously updated real-time quote of Genomma Lab stock.
Genomma Lab market facts
- Company: Genomma Lab Internacional, S.A.B. de C.V.
- ISIN: MX01LA010006
- Ticker: LAB B
- Primary exchange: Mexican Stock Exchange
- Price Lang & Schwarz (as of October 19, 2026, 4:02 p.m. CEST): EUR 0.70
- Market capitalization: MXN 14.1 billion (as of October 19, 2026)
- 52-week range: MXN 12.22-19.48 (as of October 19, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: October 21, 2026
Market context: Current market reports.
